mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Philipp E HartrampfRalph A BundschuhFranz-Xaver WeinzierlSebastian E SerflingAleksander KosmalaAnna Katharina SeitzHubert KüblerAndreas K BuckMarkus EsslerRudolf A WernerPublished in: European journal of nuclear medicine and molecular imaging (2022)
Initial increase or decrease of PSA levels is sustained in the majority of patients undergoing RLT. Sustained PSA decrease was linked to prolonged survival and men with PSA fluctuations under treatment experienced comparable survival benefits. As such, transient tumor marker oscillations under RLT should rather not lead to treatment discontinuation, especially in the absence of radiological progression.